Advanced in Pure Red Cell Aplasia

Dr. Elizabeth A. Griffiths

Hematology Oncology | Hematology | Oncology
Elm And Carlton St, 
Buffalo, NY 
Clinical Trials:Currently Recruiting for 2 Trials
Advanced in Pure Red Cell Aplasia
Elm And Carlton St, 
Buffalo, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Elizabeth Griffiths is a Hematologist Oncology specialist and a Hematologist in Buffalo, New York. Dr. Griffiths is rated as an Advanced provider by MediFind in the treatment of Pure Red Cell Aplasia. Her top areas of expertise are Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Leukemia, Chronic Myelomonocytic Leukemia (CMML), and Bone Marrow Aspiration.

Her clinical research consists of co-authoring 127 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in NY
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

Elm And Carlton St, Buffalo, NY 14263

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Multi-phase, Pharmacokinetics, Safety, and Efficacy Study of ASTX030 (Azacitidine and Cedazuridine) as Monotherapy in Subjects With Myeloid Neoplasm or in Combination With Venetoclax in Subjects With AML (AZTOUND Study)
A Multi-phase, Pharmacokinetics, Safety, and Efficacy Study of ASTX030 (Azacitidine and Cedazuridine) as Monotherapy in Subjects With Myeloid Neoplasm or in Combination With Venetoclax in Subjects With AML (AZTOUND Study)
Enrollment Status: Recruiting
Publish Date: October 02, 2025
Intervention Type: Drug
Study Drugs: Azacitidine, Cedazuridine
Study Phase: Phase 2/Phase 3
A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis
A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis
Enrollment Status: Recruiting
Publish Date: April 30, 2025
Intervention Type: Drug
Study Drug: BLU-263
Study Phase: Phase 2/Phase 3
Randomized Phase II Study to Assess the Role of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients After Chemotherapy (REMAIN TRIAL)
Randomized Phase II Study to Assess the Role of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients After Chemotherapy (REMAIN TRIAL)
Enrollment Status: Active_not_recruiting
Publish Date: October 10, 2025
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 2
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)
Enrollment Status: Active_not_recruiting
Publish Date: September 04, 2025
Intervention Type: Drug
Study Drug: ASTX727
Study Phase: Phase 1/Phase 2
A Phase 1 Study of DEC205mAb-NY ESO 1 Fusion Protein (CDX-1401) Given With Adjuvant Poly-ICLC in Conjunction With 5-Aza-2'Deoxycytidine (Decitabine) and Nivolumab in Patients With MDS or Low Blast Count AML
A Phase 1 Study of DEC205mAb-NY ESO 1 Fusion Protein (CDX-1401) Given With Adjuvant Poly-ICLC in Conjunction With 5-Aza-2'Deoxycytidine (Decitabine) and Nivolumab in Patients With MDS or Low Blast Count AML
Enrollment Status: Completed
Publish Date: July 14, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Decitabine, Nivolumab, Poly ICLC
Study Phase: Phase 1
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloid Leukemia (AML)
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloid Leukemia (AML)
Enrollment Status: Completed
Publish Date: August 27, 2024
Intervention Type: Drug
Study Drugs: Cedazuridine, Decitabine
Study Phase: Phase 3
A Phase1-2 Pharmacokinetic Guided Dose-Escalation and Dose-Confirmation Study of ASTX727, a Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 With Oral Decitabine in Subjects With Myelodysplastic Syndromes (MDS)
A Phase1-2 Pharmacokinetic Guided Dose-Escalation and Dose-Confirmation Study of ASTX727, a Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 With Oral Decitabine in Subjects With Myelodysplastic Syndromes (MDS)
Enrollment Status: Completed
Publish Date: August 27, 2024
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1, Parallel, Open-Label Study of the Safety and Tolerability, Pharmacokinetics, and Antileukemic Activity of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
A Phase 1, Parallel, Open-Label Study of the Safety and Tolerability, Pharmacokinetics, and Antileukemic Activity of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
Enrollment Status: Terminated
Publish Date: August 02, 2024
Intervention Type: Drug
Study Drugs: ASTX660, ASTX727
Study Phase: Phase 1
Evaluation of Antibody Response to High-Dose Seasonal Influenza Vaccination in Patients With Myeloid Malignancy Receiving Chemotherapy
Evaluation of Antibody Response to High-Dose Seasonal Influenza Vaccination in Patients With Myeloid Malignancy Receiving Chemotherapy
Enrollment Status: Completed
Publish Date: June 06, 2023
Intervention Type: Biological
Study Drug: Trivalent Influenza Vaccine
Study Phase: Early Phase 1
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: June 16, 2021
Intervention Type: Drug
Study Drugs: Rigosertib, Azacitidine
Study Phase: Phase 1/Phase 2
A Phase II Study of Intensive Salvage Therapy Followed by Enasidenib for Patients With AML Harboring Mutations in IDH2 Who Have Failed or Been Refractory to One Prior Line of Therapy
A Phase II Study of Intensive Salvage Therapy Followed by Enasidenib for Patients With AML Harboring Mutations in IDH2 Who Have Failed or Been Refractory to One Prior Line of Therapy
Enrollment Status: Withdrawn
Publish Date: March 10, 2021
Intervention Type: Procedure, Drug
Study Phase: Phase 2
View 10 Less Clinical Trials

127 Total Publications

NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 2.2025.
NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 2.2025.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 12, 2025
Similar Doctors
Distinguished in Pure Red Cell Aplasia
Dr. James T. Conway
Hematology Oncology
Distinguished in Pure Red Cell Aplasia
Dr. James T. Conway
Hematology Oncology
295 Essjay Rd, 
Williamsville, NY 
 (7.6 miles away)
716-630-1039
Languages Spoken:
English
See accepted insurances

James Conway is a Hematologist Oncology provider in Williamsville, New York. Dr. Conway is rated as an Advanced provider by MediFind in the treatment of Pure Red Cell Aplasia. His top areas of expertise are Pure Red Cell Aplasia, Ataxia-Pancytopenia Syndrome, Shwachman-Diamond Syndrome, and Acquired Amegakaryocytic Thrombocytopenia.

Experienced in Pure Red Cell Aplasia
Dr. Kenan Onel
Medical Genetics | Hematology | Oncology
Experienced in Pure Red Cell Aplasia
Dr. Kenan Onel
Medical Genetics | Hematology | Oncology

Roswell Park Cancer Institute

Elm And Carlton St, 
Buffalo, NY 
 (0.1 miles away)
716-845-2300
Languages Spoken:
English

Kenan Onel is a Medical Genetics specialist and a Hematologist in Buffalo, New York. Dr. Onel is rated as an Advanced provider by MediFind in the treatment of Pure Red Cell Aplasia. His top areas of expertise are Pineoblastoma, Multisystem Inflammatory Syndrome in Children (MIS-C), Pineocytoma, and Aase Syndrome.

Experienced in Pure Red Cell Aplasia
Dr. Philip L. Mccarthy
Hematology Oncology | Transplant Surgery
Experienced in Pure Red Cell Aplasia
Dr. Philip L. Mccarthy
Hematology Oncology | Transplant Surgery

Roswell Park Cancer Institute

Elm And Carlton St, 
Buffalo, NY 
 (0.1 miles away)
716-845-2300
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Philip Mccarthy is a Hematologist Oncology specialist and a Transplant Surgeon in Buffalo, New York. Dr. Mccarthy is rated as a Distinguished provider by MediFind in the treatment of Pure Red Cell Aplasia. His top areas of expertise are Multiple Myeloma, Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Bone Marrow Transplant, and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Griffiths's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 19 Advanced Conditions
View All 25 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile